Advertisement.

STLT Projected Dividend Yield

Spotlight Innovation Inc ( OTCBB : STLT )

Spotlight Innovation is a pharmaceutical company. Co.'s focus areas include, cancer, pain management, Zika virus infection, spinal muscular atrophy and refractory glaucoma. Co.'s subsidiary, Celtic Biotech Iowa, Inc. develops therapies derived from snake venom for the treatment of solid cancers and pain in humans. Co.'s subsidiary, Caretta Therapeutics, LLC will commercialize homeopathic products derived from cobra and venom, to treat chronic pain. Co. commercialize STL-182, an orally-available small molecule. Co. is developing drugs to treat patients infected with the Zika virus. Co. invests in Solx, Inc. (Solx). Solx's main product is the SOLX Gold Shunt™, an implantable drainage device.

20 YEAR PERFORMANCE RESULTS

STLT Dividend History Detail
STLT Dividend News
STLT Competitors News

# of Shares: 0

Closing Price: 0.00

Current Market Value: 0.00

Cost Basis: 0.00

Date Acquired:

Dividend Cash Flow
Year	Annual Dividend	Dividend Growth	# of Shares	Annual Dividend Income	Yield On Cost %
2014	0.00	0%	0	$ 0.00	0.00%
2015	0.00	0%	0	$ 0.00	0.00%
2016	0.00	0%	0	$ 0.00	0.00%
2017	0.00	0%	0	$ 0.00	0.00%
2018	0.00	0%	0	$ 0.00	0.00%
2019	0.00	0%	0	$ 0.00	0.00%
2020	0.00	0%	0	$ 0.00	0.00%
2021	0.00	0%	0	$ 0.00	0.00%
2022	0.00	0%	0	$ 0.00	0.00%
2023	0.00	0%	0	$ 0.00	0.00%
2024	0.00	0%	0	$ 0.00	0.00%
2025	0.00	0%	0	$ 0.00	0.00%
Using the current years Dividend Growth rate of 0% and projecting 0% forward the annual dividend income in 10/yrs would be $ 0.00 with a yield on cost % of 0.00%
Rolling Last 4 qtrs dividends total $ 0.00 and Previous last 4 qtrs dividends total $ 0.00
Dividend 1 Yr Growth = ( 0.00 – 0.00 ) × 100 = 0% (Click the Edit pencil if you want to modify the forward dividend growth rate projection) 0.00

Year	Declaration Date	Ex-Dividend Date	Record Date	Payable Date	Dividend $ Amount
Total:					0.0000